The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma

Lu, Lingyun; Dai, Zhehao; Luo, Qin; Lv, Guohua

doi:10.3892/mmr.2017.8080

Cited by 12 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CASC2 overexpression also inhibited the migration and invasion of BC cells. These findings demonstrated that CASC2 acted as a tumor suppressor in BC tissues and cells, which was in accordance with the function of CASC2 identified in other cancer tissues (30).…”

Section: Discussionsupporting

confidence: 88%

Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway

Ze-jun

Wang

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

Cancer susceptibility candidate 2 (CASC2), a long non-coding RNA (lncRNA), has been demonstrated to be a tumor suppressor in several types of cancer. However, the role and mechanism of CASC2 in breast cancer (BC) have not been investigated. In the present study, the expression and functions of CASC2 in BC were investigated. The expression of CASC2 was significantly decreased in BC tissues and cells compared with adjacent normal tissues and mammary epithelial cells, respectively. CASC2 overexpression inhibited the viability, migration and invasion, and elevated apoptosis of BC cells. In addition, CASC2 acted as a competing endogenous RNA for hsa-microRNA (miR)-96-5p and regulated the expression of its target gene, synoviolin (SYVN1). In miR-96-5p-overexpressed MDA-MB-231 cells, cell viability, migration and invasion was increased, and cell apoptosis was decreased, which was reversed by the upregulation of SYVN1. Taken together, the present study data indicated that decreased SYVN1 expression was a tumor suppressor, which inhibited the growth and metastasis of BC through the miR-96-5p/SYVN1 axis.

show abstract

Section: Discussionsupporting

confidence: 88%

Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway

Ze-jun

Wang

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…Long noncoding RNAs (lncRNAs), with 200 nucleotides in length, have been considered as transcriptional or posttranscriptional regulators of gene expression. 8 Due to the critical regulation on cell proliferation, migration and invasion, 9 lncRNAs are recently acquired great attention in cancer research. lncRNA hepatocyte nuclear factor 1 homeobox A (HNF1A)-antisense RNA 1 (AS1) is a newly reported lncRNA located on chromosome 13q33.2.…”

Section: Introductionmentioning

confidence: 99%

lncRNA HNF1A‐AS1 modulates non–small cell lung cancer progression by targeting miR‐149‐5p/Cdk6

Liu

Chen

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Growing evidence have shown the important regulation of lncRNAs (long noncoding RNAs) in non–small cell lung cancer (NSCLC). lncRNA hepatocyte nuclear factor 1 homeobox A (HNF1A)‐antisense RNA 1 (AS1), an “oncogene”, was reported to regulate human tumors progression. However, the molecular mechanism of HNF1A‐AS1 involved in the development of NSCLC is still under investigation. In the current study, we found that HNF1A‐AS1 was relatively upregulated in both NSCLC patient tissues and cell lines. Functional studies established that overexpression of HNF1A‐AS1 promoted cell proliferation, cell cycle, invasion, and migration of NSCLC cells in vitro. The promotion abilities of HNF1A‐AS1 on NSCLC cell progression were suppressed via knockdown of HNF1A‐AS1. miR‐149‐5p was then proved to be a novel target of HNF1A‐AS1, whose expression was negatively correlated with HNF1A‐AS1 in NSCLC patient tissues and cell lines. HNF1A‐AS1 increased the expression of cyclin‐dependent kinase 6 (Cdk6) via sponging with miR‐149‐5p. Gain‐ and loss‐of‐functional studies indicated that HNF1A‐AS1 promoted NSCLC progression partially through inhibition of miR‐363‐3p and induction of Cdk6. Subcutaneous xenotransplanted tumor model confirmed that interference of HNF1A‐AS1 suppressed the tumorigenic ability of NSCLC via upregulation of miR‐149‐5p and downregulation of Cdk6 in vivo. In conclusion, our findings clarified the biologic significance of the HNF1A‐AS1/miR‐149‐5p/Cdk6 axis in NSCLC progression and provided novel evidence that HNF1A‐AS1 may be a new potential therapeutic target for the treatment of NSCLC.

show abstract

“…Up to now, the association between CASC2 and related clinic features is not clear even some is opposite, and the quality of present studies is not good enough. For instance, some studies lack multivariate analysis of clinic pathologic factors for overall survival 21 , 25 , 27 , besides, some studies only provided a Kaplan-Meier curve, but didn't have a specific value of HR 20 , 21 .In addition, the sample of some study is too small 23 .Thus, we generalized and analyzed the clinicopathologic significance and prognostic value of CASC2 in cancer patients. The present comprehensive meta-analysis pooled 11 independent studies with 765 cancer patients and the results indicated that enforced CASC2 pression was a protective factor for OS in cancer patients (HR=0.43, 95% CI: 0.33-0.55, P =0.000).…”

Section: Discussionmentioning

confidence: 99%

The value of long noncoding RNA CASC2 as a biomarker of prognosis in carcinomas: a meta-analysis

Yan¹,

Zhu²,

Li³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Lnc RNA Cancer Susceptibility Candidate 2(CASC2) has been shown to be aberrantly expressed in multiple types of cancer and might serve as a prognosis biomarker. The present meta-analysis was conducted to investigate whether the expression of CASC2 was associated with prognosis or clinicopathological features in correlative cancers. A total of 11 studies with 765 cancer patients were included by searching the electronic databases, the results found a significant association between high expression of CASC2 and longer OS in cancer patients (HR=0.43, 95% CI: 0.33-0.55, P =0.000).In addition, a significant correlation was observed between high level of CASC2 and earlier TNM stage(OR = 0.30, 95% CI =0.21-0.43, P < 0.001), smaller tumor size(OR = 0.28, 95% CI =0.12-0.66, P =0.004), better tumor differentiation(OR = 0.42, 95% CI =0.27-0.66, P =0.0002). In conclusion, CASC2 can serve as a novel marker predicting the prognosis and clinicopathological features in various cancers.

show abstract

The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma

Cited by 12 publications

References 27 publications

Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway

Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway

lncRNA HNF1A‐AS1 modulates non–small cell lung cancer progression by targeting miR‐149‐5p/Cdk6

The value of long noncoding RNA CASC2 as a biomarker of prognosis in carcinomas: a meta-analysis

Contact Info

Product

Resources

About